Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial ...
Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α ...